505 related articles for article (PubMed ID: 32838716)
1. Drug Discovery by Drug Repurposing: Combating COVID-19 in the 21st Century.
Sanghai N; Shafiq K; Tranmer GK
Mini Rev Med Chem; 2021; 21(1):3-9. PubMed ID: 32838716
[TBL] [Abstract][Full Text] [Related]
2. Understanding the binding mechanism for potential inhibition of SARS-CoV-2 Mpro and exploring the modes of ACE2 inhibition by hydroxychloroquine.
Choudhury M; Dhanabalan AK; Goswami N
J Cell Biochem; 2022 Feb; 123(2):347-358. PubMed ID: 34741481
[TBL] [Abstract][Full Text] [Related]
3. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Wang M; Cao R; Zhang L; Yang X; Liu J; Xu M; Shi Z; Hu Z; Zhong W; Xiao G
Cell Res; 2020 Mar; 30(3):269-271. PubMed ID: 32020029
[No Abstract] [Full Text] [Related]
4. [The medicinal treatment of COVID-19: a brief update].
de Boer MGJ; Gieling EM; van der Linden PD; Sinha BNM; Vollaard AM
Ned Tijdschr Geneeskd; 2020 Nov; 164():. PubMed ID: 33331727
[TBL] [Abstract][Full Text] [Related]
5. Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action.
Yousefi H; Mashouri L; Okpechi SC; Alahari N; Alahari SK
Biochem Pharmacol; 2021 Jan; 183():114296. PubMed ID: 33191206
[TBL] [Abstract][Full Text] [Related]
6. A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19.
Maciorowski D; Idrissi SZE; Gupta Y; Medernach BJ; Burns MB; Becker DP; Durvasula R; Kempaiah P
SLAS Discov; 2020 Dec; 25(10):1108-1122. PubMed ID: 32942923
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 Drugs Chloroquine and Hydroxychloroquine, but Not Azithromycin and Remdesivir, Block hERG Potassium Channels.
Szendrey M; Guo J; Li W; Yang T; Zhang S
J Pharmacol Exp Ther; 2021 May; 377(2):265-272. PubMed ID: 33674391
[TBL] [Abstract][Full Text] [Related]
8. Repurposing antimalarials and other drugs for COVID-19.
Schlagenhauf P; Grobusch MP; Maier JD; Gautret P
Travel Med Infect Dis; 2020; 34():101658. PubMed ID: 32247925
[No Abstract] [Full Text] [Related]
9. Facts and Myths: Efficacies of Repurposing Chloroquine and Hydroxychloroquine for the Treatment of COVID-19.
Al-Bari AA
Curr Drug Targets; 2020; 21(16):1703-1721. PubMed ID: 32552642
[TBL] [Abstract][Full Text] [Related]
10. A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2.
Simonis A; Theobald SJ; Fätkenheuer G; Rybniker J; Malin JJ
EMBO Mol Med; 2021 Jan; 13(1):e13105. PubMed ID: 33015938
[TBL] [Abstract][Full Text] [Related]
11. A Review on Remdesivir: A Broad-spectrum Antiviral Molecule for Possible COVID-19 Treatment.
Khazir J; Maqbool T; Mir BA
Mini Rev Med Chem; 2021; 21(17):2530-2543. PubMed ID: 33596800
[TBL] [Abstract][Full Text] [Related]
12. Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes.
Choi SW; Shin JS; Park SJ; Jung E; Park YG; Lee J; Kim SJ; Park HJ; Lee JH; Park SM; Moon SH; Ban K; Go YY
Antiviral Res; 2020 Dec; 184():104955. PubMed ID: 33091434
[TBL] [Abstract][Full Text] [Related]
13. Remdesivir (GS-5734) in COVID-19 Therapy: The Fourth Chance.
Moirangthem DS; Surbala L
Curr Drug Targets; 2021; 22(12):1346-1356. PubMed ID: 33267759
[TBL] [Abstract][Full Text] [Related]
14. Drug Discovery of Small Molecules for the Treatment of COVID-19: A Review on Clinical Studies.
Goel B; Bhardwaj N; Tripathi N; Jain SK
Mini Rev Med Chem; 2021; 21(12):1431-1456. PubMed ID: 33371848
[TBL] [Abstract][Full Text] [Related]
15. Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19.
Blaess M; Kaiser L; Sommerfeld O; Csuk R; Deigner HP
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670304
[TBL] [Abstract][Full Text] [Related]
16. The lysosome: A potential juncture between SARS-CoV-2 infectivity and Niemann-Pick disease type C, with therapeutic implications.
Ballout RA; Sviridov D; Bukrinsky MI; Remaley AT
FASEB J; 2020 Jun; 34(6):7253-7264. PubMed ID: 32367579
[TBL] [Abstract][Full Text] [Related]
17. Synergistic and Antagonistic Drug Combinations against SARS-CoV-2.
Bobrowski T; Chen L; Eastman RT; Itkin Z; Shinn P; Chen CZ; Guo H; Zheng W; Michael S; Simeonov A; Hall MD; Zakharov AV; Muratov EN
Mol Ther; 2021 Feb; 29(2):873-885. PubMed ID: 33333292
[TBL] [Abstract][Full Text] [Related]
18. Are there any Therapeutic Options Currently Available for Wuhan Coronavirus?
Carradori S
Antiinflamm Antiallergy Agents Med Chem; 2020; 19(2):85-87. PubMed ID: 32213152
[No Abstract] [Full Text] [Related]
19. Antimalarials as Antivirals for COVID-19: Believe it or Not!
Saha BK; Bonnier A; Chong W
Am J Med Sci; 2020 Dec; 360(6):618-630. PubMed ID: 32950177
[TBL] [Abstract][Full Text] [Related]
20. COVID-19: Antiviral Agents, Antibody Development and Traditional Chinese Medicine.
Guan W; Lan W; Zhang J; Zhao S; Ou J; Wu X; Yan Y; Wu J; Zhang Q
Virol Sin; 2020 Dec; 35(6):685-698. PubMed ID: 32997322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
